Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413950 | 0.83 | TSHR (0.41) | ALDH1A1KEAP1TSHR | |
| SCHEMBL18946174 | 0.83 | KEAP1 (0.34) | ALDH1A1KEAP1 | |
| SCHEMBL5108673 | 0.80 | GABRA1 (0.43) | ALDH1A1KEAP1GABRA1GABRG2GABRB3 | |
| SCHEMBL12702042 | 0.80 | FBP1 (0.32) | KEAP1GABRA1GABRG2GABRB3GABRB2 | |
| SCHEMBL22426455 | 0.79 | HCAR2 (0.32) | — | |
| SCHEMBL11888072 | 0.75 | KEAP1 (0.32) | ALDH1A1KEAP1GABRA1GABRG2GABRB3 | |
| SCHEMBL23339938 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11082415 | 0.72 | ESR1 (0.31) | — | |
| SCHEMBL19674138 | 0.72 | KEAP1 (0.34) | KEAP1 | |
| SCHEMBL12263142 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365543-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11673884-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | Foresee Pharmaceuticals Co., Inc. (TW) | 2023-06-13 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-10842798-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9656974-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9598447-B2 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1771450-B1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARM INC (US) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | ALDH1A1 2515/4885KEAP1 1486/4885GABRA1 245/4885 |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885KEAP1 1001/4885GABRA1 638/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885KEAP1 1854/4885GABRA1 269/4885 |
| US-20230365543-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | ALDH1A1 2785/4885KEAP1 1159/4885GABRA1 4860/4885 |
| US-11673884-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | ALDH1A1 1950/4885KEAP1 808/4885GABRA1 4846/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | ALDH1A1 4239/4885KEAP1 910/4885GABRA1 2547/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | ALDH1A1 2971/4885KEAP1 1841/4885GABRA1 252/4885 |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | ALDH1A1 143/4885KEAP1 74/4885GABRA1 2502/4885 |
| US-10842798-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885KEAP1 1001/4885GABRA1 638/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885KEAP1 1001/4885GABRA1 638/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885KEAP1 791/4885GABRA1 1072/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885KEAP1 691/4885GABRA1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.